MedTrace Logo

Exploratory Drug Interaction Study Between SMIs and DOACs

NCT05732350 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2024-03-06

No results posted yet for this study

Summary

The main objective of this study is to investigate the effect of small molecule inhibitors (SMIs), used in targeted therapy for tumours, on direct oral anticoagulants (DOACs).

Conditions

Sponsors & Collaborators

  • Radboud University Medical Center

    collaborator OTHER

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Robin van Geel, PharMD, PhD · Maastricht UMC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2023-10-01
Completion
2024-02-29

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05732350 on ClinicalTrials.gov